Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X9RG
|
|||
| Former ID |
DAP000214
|
|||
| Drug Name |
Butorphanol
|
|||
| Synonyms |
Beforal; Butorfanol; Butorphanolum; Moradol; Stadol; Butorphanol tartrate; BC-2627; Beforal (TN); Butorfanol [INN-Spanish]; Butorphanolum [INN-Latin]; L-BC 2627; Moradol (TN); Butorphanol (USAN/INN); Butorphanol [USAN:BAN:INN]; Levo-BC-2627; (-)-17-(Cyclobutylmethyl)morphinan-3,14-diol; (-)-N-cyclobutylmethyl-3,14-dihydroxymorphinan; (-)-butorphanol; 17-(CYCLOBUTYLMETHYL)MORPHINAN-3,14-DIOL
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pain [ICD-11: MG30-MG3Z] | Approved | [1], [2] | |
| Therapeutic Class |
Analgesics
|
|||
| Company |
Apotex Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H29NO2
|
|||
| Canonical SMILES |
C1CCC2(C3CC4=C(C2(C1)CCN3CC5CCC5)C=C(C=C4)O)O
|
|||
| InChI |
1S/C21H29NO2/c23-17-7-6-16-12-19-21(24)9-2-1-8-20(21,18(16)13-17)10-11-22(19)14-15-4-3-5-15/h6-7,13,15,19,23-24H,1-5,8-12,14H2/t19-,20+,21-/m1/s1
|
|||
| InChIKey |
IFKLAQQSCNILHL-QHAWAJNXSA-N
|
|||
| CAS Number |
CAS 42408-82-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9081, 14801765, 14875085, 17397351, 32960763, 48415674, 49992740, 50631323, 57371628, 92729940, 93166707, 103205944, 104098285, 126666040, 134224509, 135000864, 136280316, 137005108, 139157626, 160963956, 163074576, 164837504, 175265477, 179150474, 198993287, 223365926, 223670035, 224782792, 226395864, 241079392, 250136746, 252346885
|
|||
| ChEBI ID |
CHEBI:3242
|
|||
| ADReCS Drug ID | BADD_D00324 ; BADD_D00325 | |||
| SuperDrug ATC ID |
N02AF01
|
|||
| SuperDrug CAS ID |
cas=042408822
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor delta (OPRD1) | Target Info | Agonist | [3] |
| KEGG Pathway | cGMP-PKG signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Opioid proenkephalin pathway | ||||
| Opioid proopiomelanocortin pathway | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7591). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 075046. | |||
| REF 3 | Butorphanol: effects of a prototypical agonist-antagonist analgesic on kappa-opioid receptors. J Pharmacol Sci. 2005 Jun;98(2):109-16. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.